67346-60-5

Basic information

• Product Name: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane
• Synonyms: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane;(R)-N-benzyl-1-(4-methoxyphenyl)propan-2-amine
• CAS NO: 67346-60-5
• Molecular Formula: C₁₇H₂₁NO
• Molecular Weight: 255.35474
• Mol File: 67346-60-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 377.8±22.0 °C(Predicted)
• Appearance: /
• Density: 1.024±0.06 g/cm3(Predicted)
• PKA: 9.54±0.19(Predicted)
• CAS DataBase Reference: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(67346-60-5)
• EPA Substance Registry System: (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane(67346-60-5)

Safety Data

• Hazardous Substances Data: 67346-60-5(Hazardous Substances Data)

Usage

Description

(R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane, also known as the R enantiomer of 1-(4-Methoxyphenyl)-2-(benzylamino)propane (M260970), is an essential intermediate in the synthesis of Formoterol Fumarate (F693401). (R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane plays a crucial role in the pharmaceutical industry due to its involvement in the production of a significant medication.

Uses

Used in Pharmaceutical Industry:
(R)-(-)-1-(4'-methoxyphenyl)-2-benzylaminopropane is used as a key intermediate in the synthesis of Formoterol Fumarate (F693401) for its role in creating a medication that serves various therapeutic purposes. Formoterol Fumarate is a long-acting beta-2 adrenergic agonist (LABA) used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It helps to relax the muscles in the airways and improve breathing for patients suffering from these respiratory conditions.

Upstream product

• 122-84-9 4-methoxybenzyl methyl ketone 
• 100-46-9 benzylamine 
• 245759-64-2 (R)-N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amine L-mandelate 
• 43229-65-8 [2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amine 
• 1096141-37-5 C₁₇H₁₉NO 
• 17199-29-0 (S)-Mandelic acid 
• 104-01-8 4-Methoxyphenylacetic acid 
• 245759-64-2 N-benzyl-1-(4-methoxyphenyl)propan-2-amine mandalate salt 
• 1049695-95-5 benzyl-[2-(4-methoxy-phenyl)-1-methyl-ethyl]-amine; hydrochloride 
• 58993-79-6 (R)-(-)-p-methoxyamphetamine 
• 100-52-7 benzaldehyde 

Downstream Products

• 245759-65-3 (R,R)-3-nitro-α-[[[2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol 
• 1026431-67-3 C₃₉H₄₁NO₄ 
• 67346-50-3 (S,R)-Formoterol 
• 73573-87-2 (R,R)-formoterol 
• 289657-26-7 (R,R)-3-amino-α-[[[2-(4-methoxyphenyl)-1-methylethyl](phenyl methyl)amino]methyl]-4-(phenylmethoxy)-benzenemethanol 
• 289657-25-6 (S)-1-(3-Amino-4-benzyloxy-phenyl)-2-{benzyl-[(R)-2-(4-methoxy-phenyl)-1-methyl-ethyl]-amino}-ethanol 
• 188690-83-7 N-[5-[(1R)-Hydroxy-2-[[(1R)-methyl-2-(4-methoxyphenyl)ethyl](phenylmethyl)amino]ethyl]-2-(phenylmethoxy)phenyl]-formamide 
• 1042738-15-7 5-[[[(1R)-2-(4-methoxyphenyl)-1-methylethyl](phenylmethyl)amino]acetyl]-8-(phenylmethoxy)-(1H)-quinolin-2-one monohydrochloride 
• 1122063-39-1 4-(2-(benzylamino)propyl)phenol 
• 1198769-18-4 (R)-4-benzyloxy-3-nitro-α-(N-benzyl-N-(1-methyl-2-p-methoxyphenylethyl)amino)acetophenone 

Relevant articles and documents

Direct Reductive Amination of Carbonyl Compounds with H2 Using Heterogeneous Catalysts in Continuous Flow as an Alternative to N-Alkylation with Alkyl Halides

A general continuous-flow procedure for direct reductive amination of secondary and primary amines with aromatic and aliphatic aldehydes as well as ketones is reported. The use of hydrogen gas and commercially available Pt/C as a heterogeneous catalyst is a key. In addition to exhibiting an excellent functional group tolerance, this method allows the fast formation of C?N bonds without production of any hazardous chemical waste. Applications to the synthesis of key intermediates toward active pharmaceutical ingredients (Donepezil and Arformoterol/Tamsulosin) are also described. (Figure presented.).

PROCESS FOR THE PREPARATION OF ARFORMOTEROL OR SALT THEREOF

Provided is an improved process for the preparation of arformoterol L-(+)-tartrate, and more specifically provided is a novel process for the preparation of arformoterol L-(+)-tartrate via arformoterol D-(?)-tartrate.

METHOD FOR PRODUCING NOVEL ORGANOMETALLIC COMPLEX AND AMINE COMPOUND

The purpose of the invention is to provide a novel organometallic compound that can be utilized as a catalyst having high generality, high activity, and excellent functional group selectivity. The invention pertains to a novel organometallic compound represented by general formula (1) that catalyzes a reductive amination reaction.